

## Height-Growth Evaluation

As part of the medical examination, height was measured by experienced medical workers at the start of imatinib treatment and at follow-up visits. Height data were converted to numbers with SDs using age- and sex-adjusted Japanese norms to give SDS. Growth while on imatinib therapy was assessed using cumulative change in height-SDS ( $\Delta$ SDS) from the start of imatinib treatment to the annual follow-up time points. Minimum height- $\Delta$ SDS was determined as the lowest value of annually calculated height- $\Delta$ SDS in each patient. Average dose of imatinib  $d_{ave}$  ( $\text{mg}/\text{m}^2$ ) for an individual during the administration period ( $i$ ) from 1 through  $n$  during  $l$ -year treatment was calculated using the following formulas:

$$\bar{d} = \frac{\sum_{i=1}^n d_i m_i}{\sum_{i=1}^n m_i}, \overline{BSA} = \frac{\sum_{j=1}^l BSA_j}{\sum_{j=1}^l k_j}, \text{ and } d_{ave} = \frac{\bar{d}}{\overline{BSA}},$$

where  $d$  is the dose of imatinib,  $m$  is the number of days of imatinib administration, and  $BSA$  is body surface area (BSA).  $BSA$  in the  $j$ th year ( $BSA_j$ ) was calculated from data obtained at the observation time point closest to the  $j$ th full-year point within 6 months. The value of  $k_j$  is 1 if  $BSA_j$  is available at the  $j$ th year and 0 otherwise. The data after reaching final height were censored for 2 patients. The final height was defined as the maximum height measured when height increase velocity slowed to  $<1$  cm per year. In this study, age threshold equivalent to the onset of puberty was defined as 9 years for girls and 11 years for boys, as generally agreed upon by pediatricians.

## Statistical Analyses

Statistical differences in height-SDS between 2 time points—at the commencement of imatinib treatment and at final follow-up—within the cohort were assessed using the Wilcoxon signed-rank test. Statistical differences between the 2 subgroups classified according to minimum height- $\Delta$ SDS were assessed using the Mann-Whitney  $U$  test. The statistical differences among the 3 subgroups classified according to the


average imatinib dose were evaluated using the Steel-Dwass test. The statistical differences among all annually calculated height- $\Delta$ SDS values during imatinib therapy in prepubertal and pubertal children at the commencement of imatinib treatment were assessed using the Tukey-Kramer honestly significant difference test.

## Results

The median age at diagnosis was 9 years (range, 2-15 years). The median average imatinib dose was  $287 \text{ mg}/\text{m}^2$  (range,  $161\text{-}543 \text{ mg}/\text{m}^2$ ), and median follow-up was 34 months (range, 10-88 months). The overall median height of the 48 children was nearly normal at the start of imatinib treatment (median height-SDS, 0.01; range,  $-2.30$  to  $1.50$ ), but was decreased significantly at the final measurement, with a median height-SDS of  $-0.85$  (range,  $-2.80$  to  $1.30$ ) ( $P < .001$ , Wilcoxon signed-rank test), indicating that imatinib adversely affected growth (Figure 1, A and B). Height  $<-2$  SD at the last follow-up was observed in 6 children (12.5%), excluding 1 child whose height was  $<-2$  SD at the start of imatinib treatment. A decrease in height-SDS of  $>0.5$  SD was observed in 25 children (52.1%), including 16 (33.3%) with a decrease of  $>1$  SD during imatinib treatment. The median minimum annually calculated height- $\Delta$ SDS during follow-up was  $-0.61$  (range,  $-2.20$  to  $0.60$ ) (Figure 1, C).

We next divided the study cohort according to their minimum height- $\Delta$ SDS into 2 subgroups:  $<-0.5$  ( $n = 25$ ) and  $\geq -0.5$  ( $n = 23$ ). Sex distribution, average imatinib dose, and proportion of patients with hydroxyurea administration were comparable between the 2 subgroups (Table). The greatest significant difference observed between the 2 subgroups was age at initiation of imatinib treatment. The proportion of prepubertal children was significantly higher in the minimum height- $\Delta$ SDS  $<-0.5$  subgroup than in the  $\geq -0.5$  subgroup. In contrast, the  $\geq -0.5$  subgroup consisted mainly of children at pubertal age at the start of imatinib treatment.

To evaluate the relationship between administered imatinib dose and growth impairment, we divided the cohort according to the average administered dose for each individual and



**Figure 1.** Change in height-SDS during imatinib treatment. Height-SDS is shown at **A**, the commencement of imatinib treatment and **B**, at the last follow-up. **C**, Minimum height- $\Delta$ SDS during imatinib treatment. The median value is indicated above each plot.  $n$ , number of patients.

Table. Patient characteristics

	Minimum height- $\Delta$ SDS		P value
	<-0.5 (n = 25)	$\geq$ -0.5 (n = 23)	
Age at the commencement of imatinib			
Median, years	7	12	<.001
Range, years	2-12	4-15	
Prepubertal age, n (%) <sup>*</sup>	23 (92.0)	4 (17.4)	<.001
Pubertal age, n (%) <sup>†</sup>	2 (8.0)	19 (82.6)	<.001
Male sex, n (%)	14 (56.0)	13 (56.5)	.9808
Duration of imatinib treatment, months, median (range)			
Prepubertal age <sup>*</sup>	42 (19-88)	14 (10-22)	.009
Pubertal age <sup>†</sup>	41 (21-60)	26 (10-61)	.406
Average imatinib dose, mg/m <sup>2</sup>			
Median	293	282	.272
Range	161-543	197-376	
Hydroxyurea administration, n (%)	2 (8.0)	3 (13.0)	.577

\*Prepubertal age: males, <11 years; females, <9 years.

†Pubertal age: males,  $\geq$ 11 years; females,  $\geq$ 9 years.

recommended pediatric doses for treating chronic-phase CML (260-340 mg/m<sup>2</sup>)<sup>6</sup> into 3 subgroups: <260 mg/m<sup>2</sup> (n = 17), 260-340 mg/m<sup>2</sup> (n = 19), and >340 mg/m<sup>2</sup> (n = 12). The median minimum height- $\Delta$ SDS of these 3 subgroups was -0.6 (median dose, 222 mg/m<sup>2</sup>), -0.48 (median dose, 293 mg/m<sup>2</sup>), and -0.85 (median dose, 360 mg/m<sup>2</sup>), respectively, indicating no significant difference among the 3 subgroups.

Representative growth charts of children at various ages at the start of imatinib treatment are shown in **Figure 2**. Growth impairment was particularly significant in children who were prepubertal at the start of imatinib treatment (**Figure 2**, A and B), and only mild growth impairment or no impairment was seen in most of the children who were pubertal at the start of imatinib treatment (**Figure 2**, C and D). However, the prepubertal children with growth impairment regained growth velocity as they reached pubertal age (**Figure 2**, E-H).

Mariani et al<sup>2</sup> reported a 9-year-old boy who demonstrated impaired growth shortly after the start of imatinib treatment but experienced catch-up growth with the onset of puberty. Thus, to evaluate whether children at pubertal age evade growth deceleration, we dichotomized the study cohort into 2 subgroups: children who started imatinib at prepubertal age (n = 27) and those who did so at pubertal age (n = 21). In the former group, height- $\Delta$ SDS began to decline during the first year of imatinib treatment, resulting in significant deceleration in growth. In the latter group, height- $\Delta$ SDS remained steady through imatinib treatment, suggesting that imatinib has little effect on growth in pubertal children (**Figure 3**).

Collectively, our data show a high frequency of growth impairment and >0.5 SD of cumulative decrease in height-SDS in children given imatinib for chronic-phase CML. This growth impairment was seen predominantly in young children who were started imatinib at prepubertal age.


## Discussion

Imatinib is now a major option as the first-line therapy for childhood CML.<sup>6-9</sup> Thus, it is important for clinicians to be


aware of its possible long-term effects. Imatinib inhibits several tyrosine kinases, including c-abl, c-kit, c-fms, and platelet-derived growth factor (PDGF) receptors.<sup>7,10,11</sup> Several studies in adults have suggested that inhibition of c-kit, c-fms, and PDGF receptors results in modulation of bone metabolism.<sup>12-15</sup> Inhibition of osteoclasts and osteoblasts may result in dysregulated bone remodeling.<sup>11,15-17</sup> Three recently published case reports indicated growth impairment as an adverse effect of long-term imatinib treatment in children.<sup>2-4</sup> In addition, a French group reported a significant decrease in height-SDS in 22 children, with a median difference of -0.37 (range, -1.09 to 0.14;  $P < .0001$ ) during the first year of imatinib treatment.<sup>5</sup> Although the impact of imatinib on growth was noticeable in children in these previous studies, it has not yet been fully elucidated.

In our study of 48 children with chronic-phase CML, the severity of growth impairment was related to age at the start of imatinib treatment. Growth impairment was observed predominantly in children at prepubertal age compared with children at pubertal age. In children who started imatinib at prepubertal age, height- $\Delta$ SDS decreased during treatment, and in most cases, more than 2 years of continuous treatment was necessary to exhibit a reduction in height-SDS of >0.5 SD (**Figure 3**). Although 4 children who started imatinib at prepubertal age were included in the height- $\Delta$ SDS  $\geq$ -0.5 subgroup, these children were receiving imatinib for <2 years (**Table**), possibly indicating a high risk for developing severe growth impairment thereafter. We compared the distinct impact of long-term imatinib treatment on growth in prepubertal and pubertal children with CML.

Because the average imatinib dose varied among patients in our cohort, analysis was also performed according to the administered dose of imatinib. Although not significant, children exposed to imatinib doses >340 mg/m<sup>2</sup> showed a greater decrease in height-SDS compared with those exposed to lower doses, suggesting the need for further analysis to determine the correlation between imatinib dose and severity of growth impairment.



**Figure 2.** A and B, Representative height growth chart at the start of imatinib treatment of prepubertal children, and C and D, pubertal children. Growth impairment was observed in children at prepubertal age, but imatinib had little affect on growth in children at pubertal age. Impaired growth before puberty recovered as children reached pubertal age even during imatinib treatment. Catch-up growth was observed at E and F, approximately 11 years for girls, and G and H, 13 years for boys.



**Figure 3.** Height- $\Delta$ SDS during imatinib treatment of **A**, prepubertal (girls < 9 years, boys < 11 years) or **B**, pubertal children (girls  $\geq$  9 years, boys  $\geq$  11 years) in relation to age at the start of treatment. Annual height- $\Delta$ SDS is determined by subtracting height-SDS at each annual time point closest to each full-year point within  $\pm 6$  months from the start of imatinib treatment. \* $P < .05$ ; \*\* $P < .01$ ; \*\*\* $P < .001$ , Tukey-Kramer highly significant difference test.

Two previous reports demonstrated a recovery in growth velocity, one after discontinuation of imatinib treatment<sup>3</sup> and another at the onset of puberty even during imatinib treatment.<sup>2</sup> In our study, among 27 children who started imatinib at prepubertal age, 8 children were followed up over the pubertal age range; catch-up growth occurred in 4 children as they reached pubertal age, even during imatinib treatment (Figure 2, E-H). Human growth is described by the infancy-childhood-puberty growth model, and growth in puberty is dependent on the synergism between sex hormones and growth hormone (GH).<sup>18</sup> In these 4 children, noticeable catch-up growth was observed at approximately 11 years in girls (Figure 2, E and F) and 13 years in boys (Figure 2, G and H), consistent with the age at onset of the pubertal growth spurt.<sup>18</sup> These data support the hypothesis that imatinib has little effect on growth of children at pubertal age. Although more follow-up is needed to determine whether this catch-up is complete or incomplete, at least incomplete catch-up growth may be expected in the remaining 4 boys, who were only 13 years or younger at the last follow-up. Our study was performed based on generally agreed-upon prepubertal and pubertal ages, and more detailed studies are needed to determine the relationship between pubertal development and growth impairment.

Vandyke et al<sup>19</sup> recently reported that the rapid acceleration of growth plate closure resulting from the inhibition of PDGF- $\beta$  receptor signaling by imatinib caused rapid acceleration of growth plate closure. However, bone age detected by wrist and hand X-rays showed no acceleration in other studies,<sup>2,3</sup> and the mechanism associated with the growth inhibitory effect of imatinib remains uncertain. A recent juvenile mouse model study indicated that long-term imatinib treatment impaired the length growth of tubular bone predominantly in prepubertal animals.<sup>20</sup> Consistent with this mouse model, growth impairment due to imatinib may be mild during the age period when height growth is dependent

on sex hormones. Thus, imatinib may have a negative effect on GH or its functions. Indeed, Hobernicht et al<sup>21</sup> recently reported a case demonstrating iatrogenically induced GH deficiency due to tyrosine kinase inhibitor therapy for CML. However, performing a GH provocative test in all cohorts proved to be challenging, and moreover, the follow-up period was not of sufficient length for the majority of our cohort to allow determination of later effects on growth. To clarify the potential growth impairment mechanism of long-term imatinib treatment, further study with an extended follow-up period is needed to evaluate the growth recovery that likely would occur concomitantly with pubertal maturation. Because impaired bone remodeling and GH deficiency are caused by inhibition of tyrosine kinase, which is not specific to imatinib,<sup>1,21</sup> careful monitoring of growth velocity, as well as bone metabolic markers and serum insulin-like growth factor 1, is recommended for children treated with tyrosine kinase inhibitors. ■

We thank all of the participating institutions in Japanese Pediatric Leukemia/Lymphoma Study Group and all members of the Chronic Myeloid Leukemia Committee for their contributions to exact follow-up and data collection in each case.

Submitted for publication Nov 8, 2010; last revision received Feb 17, 2011; accepted Mar 22, 2011.

Reprint requests: Hiroyuki Shimada, MD, PhD, Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. E-mail: hshimada@a5.keio.jp

## References

- Suttorp M, Millot F. Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem cell transplantation. *Hematology Am Soc Hematol Educ Progr* 2010;368-76.
- Mariani S, Giona F, Basciani S, Brama M, Gnassi L. Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty. *Lancet* 2008;372:111-2.
- Kimoto T, Inoue M, Kawa K. Growth deceleration in a girl treated with imatinib. *Int J Hematol* 2009;89:251-2.
- Schmid H, Jaeger BA, Lohse J, Suttorp M. Longitudinal growth retardation in a prepubertal girl with chronic myeloid leukemia on long-term treatment with imatinib. *Haematologica* 2009;94:1171-9.
- Millot F, Baruchel A, Guilhot J, Petit A, Leblanc T, Bertrandet Y, et al. Imatinib is efficient but has a negative impact on growth in children with previously untreated chronic myelogenous leukaemia (CML) in early chronic phase (CP): results of the French National Phase IV Trial (ASH annual meeting abstract). *Blood* 2009;110:863.
- Suttorp M. Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT. *Bone Marrow Transplant* 2008;42:S40-6.
- Barr RD. Imatinib mesylate in children and adolescents with cancer. *Pediatr Blood Cancer* 2010;55:18-25.
- Millot F, Guilhot J, Nelken B, Leblanc T, De Bont ES, Békassy AN, et al. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. *Leukemia* 2006;20:187-92.
- Champagne MA, Capdeville R, Krailo M, Qu W, Peng B, Rosamilia M, et al. Imatinib mesylate (STI 571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. *Blood* 2004;104:2655-60.
- Druker BJ. Imatinib as a paradigm of targeted therapies. *Adv Cancer Res* 2004;91:1-30.

11. Fitter S, Dewar AL, Kostakis P, To LB, Hughes TP, Roberts MM, et al. Long-term imatinib therapy promotes bone formation in CML patients. *Blood* 2008;111:2538-47.
12. Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. *N Engl J Med* 2006;354:2006-13.
13. O'Sullivan S, Naot D, Callon K, Porteous F, Horne A, Wattie D, et al. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. *J Bone Miner Res* 2007;22:1679-89.
14. El Hajj Dib I, Gallet M, Mentaverri R, Sévenet N, Brazier M, Kamel S. Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity. *Eur J Pharmacol* 2006;551:27-33.
15. Vandyke K, Fitter S, Dewar AL, Hughes TP, Zannettino AC. Dysregulation of bone remodelling by imatinib mesylate. *Blood* 2010;115:766-74.
16. Dewar AL, Farrugia AN, Condina MR, Bik To L, Hughes TP, Vernon-Roberts B, et al. Imatinib as a potential antiresorptive therapy for bone disease. *Blood* 2006;107:4334-7.
17. Ando W, Hashimoto J, Nampei A, Tsuboi H, Tateishi K, Ono T, et al. Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA). *J Bone Miner Metab* 2006;24:274-82.
18. Tse WY, Hindmarsh PC, Brook CG. The infancy-childhood-puberty model of growth: clinical aspects. *Acta Paediatr Scand Suppl* 1989;356:38-43.
19. Vandyke K, Dewar AL, Fitter S, Menicanin D, To LB, Hughes TP, et al. Imatinib mesylate causes growth plate closure in vivo. *Leukemia* 2009;23:2155-9.
20. Suttorp M, Boehme J, Vaitl J, Mosch B, Pursche S, Jung R, et al. Side effects on the heart and skeleton of growing mice attributed to chronic imatinib exposure (ASH annual meeting abstract). *Blood* 2008;112:402.
21. Hobernicht SL, Schweiger B, Zeitler P, Wang M, Hunger SP. Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy. *Pediatr Blood Cancer* 2011;56:671-3.

# Continuous and High-Dose Cytarabine Combined Chemotherapy in Children with Down Syndrome and Acute Myeloid leukemia: Report from the Japanese Children's Cancer and Leukemia Study Group (JCCLSG) AML 9805 Down Study

Takashi Taga, MD,<sup>1\*</sup> Yasuto Shimomura, MD,<sup>2</sup> Yasuo Horikoshi, MD,<sup>3</sup> Atsushi Ogawa, MD,<sup>4</sup> Masaki Itoh, MD,<sup>5</sup> Masahiko Okada, MD,<sup>6</sup> Junichi Ueyama, MD,<sup>7</sup> Takeshi Higa, MD,<sup>8</sup> Arata Watanabe, MD,<sup>9</sup> Hirokazu Kanegane, MD,<sup>10</sup> Asayuki Iwai, MD,<sup>11</sup> Yutaka Saiwakawa, MD,<sup>12</sup> Kazuhiro Kogawa, MD,<sup>13</sup> Junko Yamanaka, MD,<sup>14</sup> and Masahito Tsurusawa<sup>2,15</sup>

**Background.** The aim of the JCCLSG AML 9805 Down study was to evaluate the effect of continuous and high-dose cytarabine combined chemotherapy on the survival outcome of acute myeloid leukemia (AML) with Down syndrome (DS). **Procedure.** From May 1998 to December 2006, DS patients with newly diagnosed AML were enrolled. Remission induction therapy consisted of two courses of pirarubicin, vincristine, and continuous-dose cytarabine (AVC1). The patients who achieved complete remission (CR) after two courses of AVC1 were subsequently treated with mitoxantrone and continuous-dose cytarabine (MC), etoposide and high-dose cytarabine (EC) and pirarubicin, vincristine, and continuous-dose cytarabine (AVC2).

**Results.** Twenty-four patients were enrolled. All patients were younger than 4 years and diagnosed as having acute megakaryoblastic leukemia. Twenty-one patients achieved CR. Three patients died during remission induction therapy due to serious infection. No toxic deaths were observed during remission. All but one patient maintained CR without serious complications. The 5-year overall and event-free survivals were  $87.5\% \pm 6.8\%$  and  $83.1\% \pm 7.7\%$ , respectively. **Conclusions.** Continuous and high-dose cytarabine combined chemotherapy with reduced intensity would be effective in DS children with AML. Pediatr Blood Cancer 2011;57:36–40. © 2010 Wiley-Liss, Inc.

**Key words:** AML; Clinical trials; Down syndrome

## INTRODUCTION

Down syndrome (DS) is one of the most common chromosomal abnormalities and is associated with an increased risk of leukemia [1]. The clinical and biological features of acute myeloid leukemia (AML) in DS children are quite different from those in children without DS: younger age, lower white blood cell count, and high incidence of acute megakaryoblastic leukemia [2,3]. Before the 1990s, most patients with AML with DS (AML-DS) received suboptimal therapy, resulting in poor outcomes. In 1992, high rates of event-free survival (EFS) with intensive AML treatment were reported from the pediatric oncology group (POG) [4]. After recognition of the favorable outcome of AML-DS patients treated with the AML protocol, recruitment to collaborative studies for AML-DS patients increased, but it became apparent that treatment-related toxicity was high in most series [5–7]. Since then, several collaborative groups have adapted their AML protocols for AML-DS by reducing the dosage of chemotherapeutic agents [6].

We report herein the results of the Japanese Children's Cancer and Leukemia Study Group AML 9805 Down study, which evaluated the feasibility, efficacy, and safety of continuous and high-dose cytarabine combined chemotherapy, which was adapted for DS patients by reducing dose intensity.

## PATIENTS AND METHODS

### Patients

Between May 1998 and December 2006, 24 AML patients with DS entered the Japanese Children's Cancer and Leukemia Study Group AML 9805 Down study after informed consent was obtained. Neonates with transient myeloproliferative disorder (TMD), defined as appearance of myeloid blasts within the first months of life, and those with spontaneous remission were not included. All children and adolescents less than 18 years of age with no prior treatment were eligible. The initial diagnosis of AML and its subtypes was determined according to the FAB classification by institution pathologists, with central review for most cases.

## Therapy

The scheme of treatment for the JCCLSG AML 9805 Down study is shown in Table I. Remission induction therapy consisted of two courses of AVC1 (cytarabine (Ara-C) 100 mg/m<sup>2</sup>/day continuous infusion on days 1–7, pirarubicin 25 mg/m<sup>2</sup> by 60 min infusion on days 2, and 4, and vincristine (VCR) 0.7 mg/m<sup>2</sup> on day 7).

Patients who achieved complete remission (CR) after two courses of AVC1 were subsequently treated with MC (Ara-C 100 mg/m<sup>2</sup>/day continuous infusion on days 1–5 and mitoxantrone (MIT) 3.5 mg/m<sup>2</sup> by 60 min infusion days 2–4), EC (high-dose Ara-C 1 g/m<sup>2</sup> every 12 hr on days 1–5, and etoposide 66 mg/m<sup>2</sup> by 2 h infusion on days 2–4) and AVC2 (Ara-C 100 mg/m<sup>2</sup>/day continuous infusion on days 1–5, pirarubicin 35 mg/m<sup>2</sup> by 60 min infusion on day 2, and VCR 0.7 mg/m<sup>2</sup> on day 5).

<sup>1</sup>Department of Pediatrics, Shiga University of Medical Science, Japan; <sup>2</sup>Department of Pediatrics, Aichi Medical College, Japan; <sup>3</sup>Department of Hematology and Oncology, Shizuoka Children's Hospital, Japan; <sup>4</sup>Department of Pediatrics, Niigata Cancer Center, Japan; <sup>5</sup>Department of Pediatrics, Fukushima Medical College, Japan; <sup>6</sup>Department of Pediatrics, Nagasaki University, Japan; <sup>7</sup>Department of Pediatrics, Tottori University, Japan; <sup>8</sup>Department of Pediatrics, Ryuky University, Japan; <sup>9</sup>Department of Pediatrics, Nakadori General Hospital, Japan; <sup>10</sup>Department of Pediatrics, Toyama University, Japan; <sup>11</sup>Department of Hematology and Oncology, Kagawa Children's Hospital, Japan; <sup>12</sup>Department of Pediatrics, Kanazawa Medical College, Japan; <sup>13</sup>Department of Pediatrics, National Defense Medical College, Japan; <sup>14</sup>Department of Pediatrics, International Medical Center of Japan, Japan; <sup>15</sup>Chairperson of JCCLSG, Japan

Conflict of Interest: Nothing to report.

\*Correspondence to: Takashi Taga, MD, Department of Pediatrics, Shiga University of Medical Science, Tsukinowa-cho, Seta, Ohtsu, Shiga 520-2192. E-mail: ttaga@belle.shiga-med.ac.jp

Received 2 September 2010; Accepted 5 November 2010

TABLE I. Treatment Regimen of the JCCLSG AML9805 Down Study

	Regimen	Administration	Daily dose	Days	
Induction AVC1	Cytarabine	IV (24 h)	100 mg/m <sup>2</sup>	1–7	
	Pirarubicin	IV (1 h)	25 mg/m <sup>2</sup>	2–4	
	Vincristine	IV	0.7 mg/m <sup>2</sup>	7	
	Methotrexate	IT	Age-adjusted <sup>a</sup>	1	
	Cytarabine	IT	Age-adjusted <sup>a</sup>	1, (5, 10) <sup>b</sup>	
	Hydrocortisone	IT	Age-adjusted <sup>a</sup>	1, (5, 10) <sup>b</sup>	
Consolidation	MC	Cytarabine	IV (24 h)	100 mg/m <sup>2</sup>	1–5
		Mitoxantrone	IV (1 h)	3.5 mg/m <sup>2</sup>	2–4
	EC	Cytarabine	IV (2 h)	1 g × 2 /m <sup>2</sup>	1–5
		Etoposide	IV (2 h)	66 mg/m <sup>2</sup>	2–4
	AVC2	Cytarabine	IV (24 h)	100 mg/m <sup>2</sup>	1–5
		Pirarubicin	IV (1 h)	35 mg/m <sup>2</sup>	2
		Vincristine	IV	0.7 mg/m <sup>2</sup>	5
		Methotrexate	IT	Age-adjusted <sup>a</sup>	1
		Cytarabine	IT	Age-adjusted <sup>a</sup>	1
		Hydrocortisone	IT	Age-adjusted <sup>a</sup>	1

Recommended interval of each cycle was 4 weeks. <sup>a</sup>The doses were adjusted according to patient's age as follows: younger than 1 year, methotrexate (MTX) 5 mg, cytarabine (Ara-C) 10 mg, hydrocortisone (HDC) 10 mg; younger than 2 years, MTX 8 mg, Ara-C 20 mg, HDC 15 mg; younger than 3 years, MTX 10 mg, Ara-C 30 mg, HDC 20 mg; 3 years and older, MTX 12 mg, Ara-C 40 mg, HDC 25 mg. <sup>b</sup>For CNS-positive patients. The doses were adjusted according to patient's age as follows: younger than 1 year, cytarabine (Ara-C) 20 mg, hydrocortisone (HDC) 10 mg; younger than 2 years, Ara-C 30 mg, HDC 15 mg; younger than 3 years old, Ara-C 50 mg, HDC 20 mg; 3 years and older, Ara-C 70 mg, HDC 25 mg.

Prophylactic treatment for central nervous system (CNS) leukemia was performed by intrathecal injection of Ara-C, methotrexate, and hydrocortisone on the first day of AVC1 and AVC2. An absolute neutrophil count of more than 1,500/ $\mu$ L and a platelet count of more than 75,000/ $\mu$ L were the criteria for starting the first course of consolidation therapy, and an absolute neutrophil count of more than 1,500/ $\mu$ L and a platelet count of more than 100,000/ $\mu$ L were the criteria for starting the second course.

### Definitions and Statistics

Evaluation of each treatment was performed on the 28th day. Treatment response was defined as follows: CR, less than 5% blasts in the bone marrow; partial remission (PR), less than 15% blasts; and no response (NR), more than 15% blasts or progressive disease at other sites.

CNS involvement was diagnosed if more than 5 leukocytes/ $\mu$ L were identified in the cerebrospinal fluid (CSF) in combination with detectable leukemic cells in the cytospin and/or with neurological symptoms (e.g., cranial nerve palsy).

EFS was calculated from the date of the first day of chemotherapy to last follow-up or to the first event (early death, resistant leukemia, relapse, or death from any cause). The EFS time of patients with an induction failure was calculated as zero. Toxicity was graded according to the Common Terminology Criteria for Adverse Events version 3.

Univariate comparisons of the survival data were performed using the log-rank test. The Statistical Analysis Software (SAS) computer program was used for the analysis. Follow-up data were actualized as of July 31, 2009.

## RESULTS

### Patient Characteristics

The relevant initial clinical and hematological data of the 24 patients in this study are shown in Table II. Males predominated,

*Pediatr Blood Cancer* DOI 10.1002/pbc

and all patients were younger than 4 years (median age, 17 months). The median white blood cell count was 6,500/ $\mu$ L (range 500–70,900/ $\mu$ L). All patients showed FAB M7 morphologically. No patients had CNS involvement. One patient had an extramedullary mass (skin) at initial diagnosis. Cytogenetic analysis of leukemic blasts was available for 22 patients. Favorable cytogenetics, such as inv (16) and t (8; 21), were not observed. Six patients had normal karyotypes with constitutional trisomy 21 only. The remainder had complex karyotypes with aneuploidy and translocation. GATA1 mutation was confirmed only in one patient.

Seven patients had a history of TMD. No patients of them received cytarabine therapy. Nine patients had documented congenital heart disease. Most patients had either surgically repaired defects or asymptomatic atrial septal defect or ventricular septal defect with normal function.

### Overall Outcome

Overall, 21 (87.5%) of 24 patients achieved first remission. One patient relapsed with an isolated extramedullary mass after cessation of chemotherapy. The patient has been in third remission after chemotherapy, electron beam irradiation and cord blood cell transplantation following reduced intensity conditioning. The other 20 patients remain in first CR. Estimated 5-year OS and EFS were 87.5%  $\pm$  6.8% and 82.6%  $\pm$  7.9%, respectively (Fig. 1). No patients with secondary malignancy and severe cardiotoxicity were observed. Median follow-up period for all patients was 75 (range, 0–131) months.

### Treatment-Related Mortality

Three deaths occurred that were not related to leukemia during induction therapy. Two of them occurred during the initial induction therapy, and the other occurred during second induction therapy.

**TABLE II. Patients' Characteristic in the JCCLSG AML 9805 Down Study (N = 24)**

Characteristic	No	%
Age, months		
Median	17	—
0–12	4	17
12–24	12	46
24–36	4	17
36–48	4	17
Sex		
Male	19	79
Female	5	21
History of TMD		
Yes	7	29
No	13	54
Unknown	4	17
Hepatomegaly		
Yes	10	42
No	12	50
Unknown	2	8
Splenomegaly		
Yes	10	42
No	12	50
Unknown	2	8
WBC, ×10 <sup>9</sup> /L		
Median	6.5	—
Range	2.8–70.9	—
Hb, g/dL		
Median	8.1	—
Range	3.2–11.8	—
Plt, ×10 <sup>9</sup> /L		
Median	26	—
Range	3–139	—
Cytogenetics		
Trisomy 8	5	21
Monosomy 7	4	17
Additional 21	2	8

**Toxic Events**

The incidence of grade 3 or 4 toxicity during induction and each intensification phase of therapy is shown in Table III. Three patients

died during remission-induction therapy. One death was attributable to intracranial hemorrhage with disseminated intravascular coagulation, and the others were due to sepsis. The rate of induction death was 12.5%. No toxic deaths were observed during remission.

**Prognostic Factors**

Extramedullary invasion at initial diagnosis was a significant prognostic factor for 5-year EFS on univariate analysis (*P* = 0.046). Other factors, including sex, initial age, initial WBC, history of TMD, and chromosomal abnormality, were not significant.


**DISCUSSION**

The results of the JCCLSG AML 9805 Down study, which was conducted to evaluate the efficacy and safety of continuous and high-dose cytarabine combined chemotherapy with reduced intensity for AML-DS patients were presented. All patients enrolled in our study were younger than 4 years and had a phenotype of acute megakaryocytic leukemia (AMKL), which was consistent with previous reports for AML-DS. The number of patients was limited, but this regimen appears to be highly effective because there were no non-responders, and only one patient relapsed.

Contemporary clinical trials for AML-DS children are summarized in Table IV [5–11]. Treatment strategies for AML-DS are based on reduced intensity for AML non-DS, such as BFM and our study, or on a specifically designed strategy, such as the AT/DS study and the AML99 Down study in Japan [8,9]. The EFS of these studies, including the present study, has been between 80% and 90%.

The key drugs for the treatment of AML-DS are anthracyclines, cytarabine, and etoposide; it was also confirmed by in vitro studies that AMKL-DS blasts were significantly more sensitive to these drugs than non-DS AML cells [12]. AMKL-DS blasts are especially sensitive to cytarabine, possibly to the effect of the GATA1 mutations and trisomy 21 on the levels of cytarabine-metabolizing enzymes [13].

In the BFM 98 DS study, with a 3-year EFS of 89%, high-dose cytarabine (3 g/m<sup>2</sup>) was used as intensification [6]. The authors reported that a high cure rate could be achieved in DS patients with therapy protocols including high-dose cytarabine. However, they also mentioned that it should be confirmed whether a dosage of 3 g/m<sup>2</sup> of cytarabine is necessary because of its toxicity. In



**Fig. 1.** Actuarial survival rate for the JCCLSG AML 9805 Down study. Of the 24 patients, 22 achieved CR. One patient relapsed. Two patients died during induction therapy. One patient died as a result of sepsis during the first CR. The 5-year overall survival (OS) was 87.5%, and the 5-year EFS was 82.6%.



TABLE III. Severe Adverse Events in the JCCLSG AML9805 Down Study (Grade III–IV)

Adverse events	AVC1-1 no.	n = 24 (%)	AVC1-2 no.	n = 22 (%)	MC no.	n = 21 (%)	EC no.	n = 21 (%)	AVC2 no.	n = 21 (%)
ALT/AST	5	23	2	9	0	0	1	5	0	0
Gastrointestinal	9	41	5	23	5	24	2	10	2	10
Renal	0	0	0	0	0	0	0	0	0	0
Cardiac	0	0	0	0	0	0	0	0	0	0
Pulmonary	1	5	0	0	0	0	0	0	0	0
Neurology	0	0	0	0	0	0	0	0	0	0
Pain	1	5	1	5	0	0	0	0	1	5
Fever/infection	14 (2)	64	9 (1)	41	11	52	15	71	7	33
Others	0	0	0	0	0	0	0	0	0	0

Number of patients who died.

our JCCLSG AML9805 Down study, 1 g/m<sup>2</sup> of cytarabine with etoposide was used for intensification. Serious non-hematological adverse effects, including infection, were not more frequent in this phase than in the other phase of this study (Table III). The dosage of 1 g/m<sup>2</sup> used in the present study may be sufficient for the treatment of AML-DS.

In the Japanese trial AML 99 Down study, the 4-year EFS was 83%, and treatment-related mortality was only 1.4%, which is much lower than that of recent reports for AML-DS [9]. However, relapse and induction failure were more frequent than in other reports with an intensive regimen. The regimen consisted of simple repeating of intermediate doses of pirarubicin and etoposide, so it is possible to reduce the rate of relapse and resistant disease using continuous and high-dose cytarabine combined chemotherapy, as in the JCCLSG AML9805 Down study.

As for other types of leukemia, risk-oriented therapy is proposed if any prognostic factors are identified in AML-DS. In the CCG 2891 study, patients with AML-DS who were older than 2 years had an increased risk of relapse [5]. However, in the BFM 98 DS study and in the Japanese AML 99 Down study, there was no difference in outcome between those 2 years or younger and those older than 2 years [6,9]. The present study also did not identify age older than 2 years as a risk factor, because all 7 patients older than 2 years survived without relapse after completing this protocol.

For cytogenetic factors, monosomy 7 is known to be a risk factor in children with AML [14,15]. In AML-DS, the presence of monosomy 7 adversely affected the outcome in the previous two Japanese trials, but not in the CCG 2891 study [5,8,9]. In the present study, four patients were found to have monosomy 7, and they all maintained remission. Continuous and high-dose cytarabine combined

chemotherapy might affect intensification, which negates risk factors such as age and monosomy 7.

It is important to note that only one patient relapsed in the present study. Moreover, the cumulative doses of anthracycline and etoposide in this JCCLSG AML9805 Down study were lower than in other recent reports with intensive regimens for AML-DS. No patients had developed secondary cancer or cardiac insufficiency at the time of this analysis. The survival of DS patients has become longer, and it would be more important to decrease the late toxicity by reducing the cumulative doses of antileukemic drugs for AML-DS patients.

On the contrary, treatment-related mortality occurred in 3 of 24 patients (12.5%), which is more frequent than in other recent reports with intensive regimens for AML-DS. All three patients died from infection during the initial and second courses of this protocol. We could not identify any risk factors for toxicity in these patients, such as age or cardiac disease, compared with the patients who were successfully treated by this protocol. Serious non-hematological adverse effects, including infection, were more frequent during the remission induction phase than during the intensification phase. Induction therapy with combined continuous cytarabine might be toxic for AML-DS patients, although the induction rate is high. On the other hand, toxicity during the intensification phase including high-dose cytarabine was tolerable.

On the basis of the results of the previous Japanese trials and the present study, we have designed a risk-oriented therapy protocol for our next trial with AML-DS. Patients with M2, M3 marrow after induction therapy by pirarubicin, intermediate-dose cytarabine, and etoposide classified into a high-risk group will receive the continuous and high-dose cytarabine combined regimen of this JCCLSG AML9805 Down study.

TABLE IV. Comparison of Recent Clinical Trials for AML-DS

Study	Registry (year)	N	Daunorubicin (mg/m <sup>2</sup> )	Ara-C (mg/m <sup>2</sup> )	Etoposide (mg/m <sup>2</sup> )	TRM (%)	OS (%)	EFS (%)
BFM98 for DS	1998–2003	67	220–240	23–29,000	950	5	91	89 (3y)
BFM93	NA	51	220–400	23,000	950	4	70	68 (3y)
NOPHO AML93	1988–2002	41	300	48,600	1,600	5	NA	85 (8y)
MRC AML10/12	1988–2002	46	670	10,600	NA	15	74	74 (5y)
CCG 2861/2891	1989–1999	160	320	15,800	1,600	4	79	77 (6y)
POG 9421	1995–1999	57	100	20,700	—	0	NA	79 (3y)
AT/Down	1987–1997	33	100–400	4,200	2,700	9	NA	80 (8y)
AML99 DS	2000–2004	72	250	3,500	2,250	1	84	83 (4y)
JCCLSG 9805DS	1998–2006	24	190	12,600	200	12.5	88	83 (5y)

TRM, treatment-related mortality; OS, overall survival; EFS, event-free survival; NA, not evaluated.

## ACKNOWLEDGMENT

We are grateful to all participating institutions in the JCCLSG and all members of the JCCLSG AML committee for their contributions to the thorough follow-up and data collection in each case.

## REFERENCES

1. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. *Lancet* 2000;355:165-169.
2. Kojima S, Matsuyama T, Sato T, et al. Down's syndrome and acute leukemia in children: an analysis of phenotype by use of monoclonal antibodies and electron microscopic platelet peroxidase reaction. *Blood* 1990;76:2348-2353.
3. Zipursky A, Thorner P, De Harven E, et al. Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. *Leukemia Res* 1994;18:163-171.
4. Ravindranath Y, Abella E, Krischer JP, et al. Acute myeloid leukemia in Down's syndrome in highly responsive to chemotherapy: experience on Pediatric Oncology Group AML study 8498. *Blood* 1992;80:2210-2214.
5. Gams AS, Woods WG, Alonzo TA, et al. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891. *J Clin Oncol* 2003;21:3415-3422.
6. Creutzig U, Reinhardt D, Diekamp S, et al. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. *Leukemia* 2005;19:1355-1360.
7. Rao A, Hills RK, Stiller C, et al. Treatment for myeloid leukaemia of down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. *Br J Haematol* 2006;132:576-583.
8. Kojima S, Sako M, Kato K, et al. An effective chemotherapy regimen for acute myeloid leukemia and myelodysplastic syndrome with Down's syndrome. *Leukemia* 2000;14:786-791.
9. Kudo K, Kojima S, Tabuchi K, et al. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group. *J Clin Oncol* 2007;25:5442-5447.
10. Abildgaard L, Ellebaek E, Gustafsson G, et al. Optimal treatment intensity in children with Down syndrome eloid leukaemia: data from 56 children treated on NOPHO-AML protocols and review of the literature. *Ann Haematol* 2006;85:275-280.
11. Stevens RF, Hann IM, Wheatley K, et al. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom medical research council's 10th AML trial. MRC childhood leukaemia working party. *Br J Haematol* 1998;101:130-140.
12. Zwaan CM, Kaspers GJ, Pieters R, et al. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. *Blood* 2002;99:245-251.
13. Ge Y, Stout ML, Tatman DA, et al. GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. *J Natl Cancer Inst* 2005;97:226-231.
14. Raimondi SC, Chang MN, Ravindranath Y, et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative Pediatric Oncology Group study-POG8821. *Blood* 1999;94:3707-3716.
15. Wells RJ, Arthur DC, Srivastava A, et al. Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children's Cancer Group Study 213. *Leukemia* 2002;16:601-607.

## Flow cytometric analysis of de novo acute myeloid leukemia in childhood: report from the Japanese Pediatric Leukemia/Lymphoma Study Group

Hideaki Ohta · Shotaro Iwamoto · Nobutaka Kiyokawa · Masahito Tsurusawa · Takao Deguchi · Kozo Takase · Junichiro Fujimoto · Keizo Horibe · Yoshihiro Komada

Received: 6 August 2010/Revised: 5 December 2010/Accepted: 14 December 2010/Published online: 5 January 2011  
© The Japanese Society of Hematology 2010

Immunophenotypic analysis has become a powerful tool for the correct identification of leukemic cell lineage. Our study evaluates the diagnostic utility of flow cytometric immunophenotyping of pediatric AML. We retrospectively collected data of immunophenotype from 375 cases of de novo AML studied from 1997 to 2007 at central laboratory institutions of the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG): Department of Pediatrics and Developmental Science, Mie University Graduate School of Medicine; Department of Pediatrics, Osaka University Graduate School of Medicine; Center for Clinical Research, National Center for Child Health and Development; and Department of Pediatrics, Aichi Medical University. The diagnosis of AML was made according to the French-American-British (FAB) classification based on morphology and enzyme cytochemical analysis as follows:

For the Immunological Diagnosis Committee of the Japanese Pediatric Leukemia/Lymphoma Study Group.

H. Ohta (✉)  
Department of Pediatrics,  
Osaka University Graduate School of Medicine,  
Yamadaoka 2-2, Suita, Osaka 565-0871, Japan  
e-mail: ohta@ped.med.osaka-u.ac.jp

S. Iwamoto · T. Deguchi · Y. Komada  
Department of Pediatrics and Developmental Science,  
Mie University Graduate School of Medicine,  
Tsu, Mie, Japan

N. Kiyokawa  
Department of Developmental Biology,  
National Center for Child Health and Development,  
Setagaya-ku, Tokyo, Japan

M. Tsurusawa  
Department of Pediatrics, Aichi Medical University,  
Nagakute, Aichi, Japan

M0 (acute myeloid leukemia without differentiation,  $n = 11$ ), M1 (acute myelocytic leukemia with little differentiation,  $n = 41$ ), M2 (acute myelocytic leukemia with differentiation,  $n = 113$ ), M4 (acute myelomonocytic leukemia,  $n = 47$ ), M5 (acute monocytic leukemia,  $n = 54$ ), M6 (acute erythroleukemia,  $n = 6$ ), and M7 (acute megakaryoblastic leukemia,  $n = 61$ ).

Mononuclear cells of bone marrow or peripheral blood samples were stained with various combinations of fluorescein isothiocyanate (FITC)- and phycoerythrin (PE)-labeled monoclonal antibodies against the following antigens: CD4, CD7, CD13, CD14, CD15, CD19, CD33, CD34, CD36, CD41, CD42b, CD45, CD56, CD61, CD65, CD117, glycophorin A (GPA: CD235a), and HLA-DR. Cytoplasmic MPO was also detected by anti-MPO antibody after permeabilization. Two-color flow cytometric immunophenotyping was performed by collecting 10,000 ungated list mode events. An antigen was considered as

K. Takase  
Department of Health Science Policies,  
Division of Research Development,  
Graduate School of Medical and Dental Sciences,  
Tokyo Medical and Dental University,  
Bunkyo-ku, Tokyo, Japan

J. Fujimoto  
Center for Clinical Research, National Center for Child Health  
and Development, Setagaya-ku, Tokyo, Japan

K. Horibe  
Clinical Research Center, National Hospital Organization  
Nagoya Medical Center, Nagoya, Aichi, Japan

**Table 1** Immunophenotypic profile of 375 de novo cases of acute myeloid leukemia

	CD34	CD117	HLADR	MPO	CD13	CD33	CD14	CD15	CD65	GPA	CD36	CD41	CD42b	CD61	CD7	CD4	CD19	CD56	CD45
M0 (11)	72.7 (11)	90.9 (11)	63.6 (11)	45.5 (11)	54.5 (11)	90.0 (11)	0 (11)	33.3 (9)	16.7 (6)	0 (11)	9.1 (11)	9.1 (11)	9.1 (11)	ND	54.5 (11)	9.1 (11)	9.1 (11)	45.5 (11)	90.0 (10)
M1 (41)	85.4 (41)	100 (36)	73.2 (41)	100 (41)	90.2 (41)	97.6 (41)	2.6 (39)	60.7 (28)	75.0 (20)	0 (37)	18.9 (37)	10.0 (40)	0 (36)	ND	51.2 (41)	2.7 (37)	7.3 (41)	19.5 (41)	90.9 (33)
M2 (113)	83.8 (111)	94.4 (89)	89.2 (111)	96.4 (84)	91.2 (113)	92.9 (113)	7.4 (108)	55.1 (89)	33.3 (63)	0 (93)	12.0 (92)	4.5 (112)	2.2 (92)	ND	14.3 (112)	0 (95)	24.8 (113)	36.4 (110)	97.3 (74)
M3 (42)	14.3 (42)	76.3 (38)	4.8 (42)	96.9 (32)	92.9 (42)	97.6 (42)	4.8 (42)	15.6 (32)	53.8 (26)	2.8 (36)	5.6 (36)	0 (42)	10.8 (37)	ND	0 (42)	2.7 (37)	2.4 (42)	7.1 (42)	85.2 (23)
M4 (47)	53.2 (47)	76.7 (43)	78.7 (47)	94.9 (39)	87.2 (47)	93.6 (47)	29.8 (47)	80.0 (30)	80.6 (31)	2.3 (43)	51.2 (43)	10.6 (47)	4.5 (44)	ND	8.5 (47)	23.1 (39)	2.1 (47)	15.2 (46)	94.4 (36)
M5 (54)	24.1 (54)	39.6 (48)	81.5 (54)	68.6 (35)	64.8 (54)	98.1 (54)	34.6 (52)	74.5 (47)	87.1 (31)	2.3 (43)	60.5 (43)	5.6 (54)	2.1 (48)	ND	3.7 (54)	52.1 (48)	1.9 (54)	57.4 (54)	93.8 (32)
M6 (6)	50.0 (6)	66.7 (6)	50.0 (6)	80.0 (5)	100 (6)	100 (6)	0 (6)	0 (4)	25.0 (4)	66.7 (6)	83.3 (6)	0 (6)	0 (6)	ND	33.3 (6)	16.7 (6)	0 (6)	0 (6)	60.0 (5)
M7 (61)	41.1 (56)	74.5 (51)	49.1 (57)	2.8 (36)	73.7 (57)	90.0 (60)	1.9 (53)	8.9 (45)	5.7 (35)	32.0 (50)	78.0 (50)	72.4 (58)	58.5 (53)	85.7 (14)	69.6 (56)	20.0 (50)	1.7 (58)	45.6 (57)	96.8 (31)

Values indicate proportion of positive cases (%); parentheses indicate evaluable cases, ND not done

positive, if more than 30% of the gated cells showed specific labeling above that of controls, or if positive subpopulation was distinctively identified even in <30% positive cases.

The result is summarized in Table 1. Cytoplasmic MPO expression was found in less than half of cases with M0 (45.5%), which is consistent with other reports [1, 2]. However, M0 blasts expressed CD33 (90.0%) and CD117 (90.9%), and, less frequently, CD34 (72.7%), suggesting myeloid lineage. The low expression of CD13 as compared to CD33 in our study may reflect a more mature myeloid profile in pediatric cases [1, 3]. CD7, expressed in more than half cases, is known to be expressed in a proportion of AML-M0 and M1 cases [3–5], consistent with the fact that CD7 is expressed during early stages of normal myeloid differentiation [6]. CD56 was also expressed in nearly half of cases, but only one case co-expressed CD7 and CD56 consistent with NK/myeloid-cell precursor acute leukemic cells [7].

M1 and M2 blasts expressed CD34, CD117, HLA-DR, MPO, CD13, CD33, and HLA-DR in more than 80% of cases, and less commonly CD15 and CD65. CD7 was detected in 51.2% of M1 cases, while its expression was repressed in M2. CD19, detected in 24.8% of M2 cases, was reported to be detected in 78–81% of M2 cases with t(8;21) translocation [8, 9].

M3 cells expressed CD13, CD33, and MPO at high frequency, as for M1 or M2 cells. However, the frequency of CD117 expression was 76.7%, lower than for M1 or M2 cells. A striking feature is that the expression of CD34 and HLA-DR was low, at 14.3 and 4.8%, respectively. The lack of CD34 and HLA-DR was a feature of M3 blasts [4, 5, 10].

Leukemic cells of most M4 and M5 cases expressed monocyte markers, CD15 and CD65. The less common expression of CD14 has been reported by others, particularly in M5 cases [2, 5, 10]. M4 and M5 expressed CD33 at similarly high frequencies. The progenitor-associated antigens, CD34 and CD117, were seen in a lower proportion of M5 cases, which might reflect commitment to monocytic lineage. CD4 was expressed in 52.1% of M5 cases and 23.1% of M4 cases, in line with other reports [2, 10].

We observed only six M6 cases. Leukemic erythroblasts expressed CD36 and GPA in 66.7 and 83.3% of cases, respectively. Myeloid antigens (MPO, CD13, and CD33) and hematopoietic progenitor-associated markers (CD34 and CD117) were also expressed at variable frequencies. The expression of monocytic markers (CD14 and CD15) was absent, as well as megakaryocyte-associated antigens (CD41 and CD42b).

The expression frequencies of megakaryocyte-associated antigens, CD41 and CD42b in cases with M7, were

72.4 and 58.5%, respectively. All cases expressed CD41 and/or CD42b. CD36 was expressed at a high frequency, but its expression was also seen in other subtypes (M4, M5, and M6). Myeloid antigens (CD13 and CD33) were expressed in most cases, but lack of MPO expression was observed. Hematopoietic progenitor-associated antigens (CD34 and CD117) were expressed in many cases, and CD7 was expressed in 69.6% of cases.

In conclusion, each subtype of AML possesses distinguishing features of antigen expression. Some antigens appear to be associated with certain subtypes, but are not necessarily specific. Uncommon expression must be interpreted in the context of the entire immunophenotyping profile for correct identification of AML subtypes.

**Acknowledgment** This study was supported by a grant for Clinical Cancer Research from the Ministry of Health, Labour, and Welfare of Japan.

## References

1. Bene MC, Bernier M, Casasnovas RO, Castoldi G, Doekharan D, van der Holt B, et al. Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients. *Br J Haematol.* 2001;113:737–45.
2. Behm FG. Diagnosis of childhood acute myeloid leukemia. *Clin Lab Med.* 1999;19:187–237. vii.
3. Kotylo PK, Seo IS, Smith FO, Heerema NA, Fineberg NS, Miller K, et al. Flow cytometric immunophenotypic characterization of pediatric and adult minimally differentiated acute myeloid leukemia (AML-M0). *Am J Clin Pathol.* 2000;113:193–200.
4. Creutzig U, Harbott J, Sperling C, Ritter J, Zimmermann M, Loffler H, et al. Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. *Blood.* 1995;86:3097–108.
5. Kaleem Z, Crawford E, Pathan MH, Jasper L, Covinsky MA, Johnson LR, et al. Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data. *Arch Pathol Lab Med.* 2003;127:42–8.
6. Chabannon C, Wood P, Torok-Storb B. Expression of CD7 on normal human myeloid progenitors. *J Immunol.* 1992;149:2110–3.
7. Oshimi K. Progress in understanding and managing natural killer-cell malignancies. *Br J Haematol.* 2007;139:532–44.
8. Kita K, Nakase K, Miwa H, Masuya M, Nishii K, Morita N, et al. Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. *Blood.* 1992;80:470–7.
9. Hurwitz CA, Raimondi SC, Head D, Krance R, Mirro J Jr, Kalwinsky DK, et al. Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. *Blood.* 1992;80:3182–8.
10. Campana D, Behm FG. Immunophenotyping of leukemia. *J Immunol Methods.* 2000;243:59–75.

## Assessment of Late Cardiotoxicity of Pirarubicin (THP) in Children With Acute Lymphoblastic Leukemia

Yasuto Shimomura, MD, Reizo Baba, MD, Arata Watanabe, MD, Yasuo Horikoshi, MD, Keiko Asami, MD, Nobuyuki Hyakuna, MD, Asayuki Iwai, MD, Takeshi Matsushita, MD, Kazutaka Yamaji, MD, Toshinori Hori, and Masahito Tsurusawa, MD\* for The Japanese Childhood Cancer and Leukemia Study Group (JCCLSG)

**Background.** Pirarubicin (tetrahydropyranil-adriamycin: THP) is a derivative of doxorubicin with reportedly less cardiotoxicity in adults. However no studies of cardiotoxicity in children treated with THP have been reported. This study was performed to assess the THP-induced cardiotoxicity for children with acute lymphoblastic leukemia (ALL). **Patients and Methods.** This study comprised 61 asymptomatic patients aged from 7.6 to 25.7 years old. Median follow-up time after completion of anthracycline treatment was 8.1 years (range: 1.7–12.5). The cumulative dose of THP ranged from 120 to 740 mg/m<sup>2</sup> with a median of 180 mg/m<sup>2</sup>. Patients underwent electrocardiogram (ECG), echocardiography, the 6-min walk test (6MWT), and measurements of serum brain natriuretic peptide (BNP) before and after exercise. **Results.** All subjects showed normal left ventricular function assessed by

echocardiography. Ventricular premature contraction in Holter ECG and reduced exercise tolerance in the 6MWT were detected in 2/46 (3.3%) and 5/41 (12.2%), respectively. Abnormal BNP levels were detected in 6/60 (10%) both before and after exercise. The cumulative dose of THP was significantly correlated with BNP levels after exercise ( $r = 0.27$ ,  $P = 0.03$ ), but not with any other cardiac measurements. Further analysis revealed that subjects with a high cumulative dose  $\geq 300$  mg/m<sup>2</sup> had significantly higher BNP levels after exercise compared with subjects with a low cumulative dose  $< 300$  mg/m<sup>2</sup> ( $P = 0.04$ ). **Conclusions.** No significant cardiac dysfunction was detected in long-term survivors who received THP treatment. The use of post-exercise BNP level to indicate high cardiotoxicity risk should be verified by further study. *Pediatr Blood Cancer* 2011; 57:461–466. © 2011 Wiley-Liss, Inc.

**Key words:** BNP; cardiotoxicity; childhood ALL; pirarubicin

### INTRODUCTION

During the past 30 years, the use of anthracyclines (AC) for the treatment of childhood cancers has significantly improved survival outcomes [1,2]. However, the therapeutic potential of these agents is limited by their cardiotoxicity: acute cardiotoxicity occurs immediately after treatment, early-onset chronic cardiotoxicity presents within 1 year after treatment, and late-onset chronic cardiotoxicity appears after a prolonged asymptomatic period with a latency of one or more years following AC therapy [3–5].

In children, late-onset cardiotoxicity is more common than acute or early-onset toxicity [6–11]. In an effort to reduce overall cardiotoxicity, various AC derivatives have been studied [5]. Pirarubicin (tetrahydropyranil-adriamycin: THP) is a derivative of doxorubicin (DOX) with reportedly low cardiotoxicity in adult patients [12–20]. However, these reports were limited to acute cardiotoxicity immediately after THP treatment, and there are no available data of late-onset cardiotoxicity in both adult and childhood patients [21,22]. Since the 1990s, the Japanese Childhood Cancer and Leukemia Study Group (JCCLSG) has employed THP in the treatment of acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphomas, and recently, it reported long-term patient outcomes, finding a very low incidence of congestive heart failure among survivors [23–25]. This finding led to assessment of the incidence of subclinical cardiac abnormalities among these survivors, because many previous studies had shown a considerable proportion of asymptomatic childhood cancer survivors who had received AC therapy with possible abnormalities of cardiac function or myocardial biomarkers [26–31]. That is, the importance of longer follow up has become apparent with the increasing numbers of asymptomatic cancer survivors at risk of cardiac dysfunction late in life.

In this study, THP-induced late cardiotoxicity was evaluated for asymptomatic children who received THP therapy in three consecutive JCCLSG studies (ALL911/ALL941/ALL2000). The

results showed that THP-induced late cardiac dysfunction was not detected in any subjects, but careful observation may be necessary for subjects who show elevated biomarker levels following the exercise test.

### PATIENTS AND METHODS

#### Study Population

The 33 member institutes of the JCCLSG participated in three consecutive ALL trials, and the total number of long-term survivors was 825 (161 in ALL911, 381 in ALL941, and 283 in ALL2000). This study was performed on subjects from the 7 of these hospitals which had follow-up systems for long-term survivors with the collaboration of cardiologists. In each institute, survivors who had clinical heart failure, as defined by the New York Heart Association classification (NYHA, class III–IV) [32] or cardiovascular disease were excluded. Prior written informed consent was obtained from patients or legal guardians. Finally, 61 patients (9 in ALL911, 48 in ALL941, 4 in ALL2000) were enrolled in this study (Table I). Since many survivors from ALL911 (1991–1993) are now adults with no time to participate the study, and those from ALL2000 (2000–2003) have had a very short follow-up duration, 80% of patients consisted of survivors

Additional Supporting Information may be found in the online version of this article.

Department of Pediatrics, Aichi Medical University, Aichi-gun, Aichi-ken, Japan

Conflict of interest: Nothing to declare.

\*Correspondence to: Masahito Tsurusawa, MD, Department of Pediatrics, Aichi Medical University, Aichi-gun, Aichi-ken 480-1195, Japan. E-mail: mtsuru@aichi-med-u.ac.jp

Received 24 August 2010; Accepted 9 December 2010

TABLE I. Characteristics of Patients

Sex—male:female		30:31
Age at onset (years old)		5.7 ± 3.5
Age at evaluation (years old)		14.7 ± 3.5
Follow-up period (years)		7.2 ± 2.8
Treatment protocol		
ALL 911	Total	9
	LR	2
	IR	3
	HR	4
ALL 941	Total	48
	LR	7
	IR	21
	HR	17
	HHR	3
ALL 2000	Total	4
	IR	1
	HR	3
Total dose of THP (mg/m <sup>2</sup> )		299 ± 192 (120–740; 180) <sup>a</sup>
Total dose of anthracyclins converted to THP (mg/m <sup>2</sup> )		346 ± 206 (135–812; 207) <sup>a</sup>

Data are expressed as mean ± SD. HHR, high-high-risk; HR, high-risk; IR, intermediate-risk; LR, low-risk. <sup>a</sup>The number of parenthesis shows the range and median value.

from the ALL941 (1994–1999) study. Ages ranged from 7.6 to 25.7 years old with a median of 14.7, and the median follow-up time after completion of AC therapy ranged from 1.7 to 12.5 years with a median of 8.1. Ten age-matched healthy controls were also recruited (6 males and 4 females; mean age 13.8 ± 2.4 years old). They had normal cardiac function and had not received any treatment affecting the heart, kidneys, or fluid balance before the study.

### Intralaboratory Exercise Testing

Master two-step intralaboratory testing with triple exercise loads was performed on every subject. The electrocardiogram (ECG) tracing was recorded before, immediately following, and 1 min after exercise. An abnormal ECG response was defined as a horizontal or downsloping ST segment depression of 0.10 mV (1 mm) for 80 msec [33].

### Natriuretic Peptide

Blood samples for measuring brain natriuretic peptide (BNP) before intralaboratory exercise testing were obtained during fasting in the morning, and further samples were obtained after the exercise test. 1.5 ml of blood was drawn into ice-chilled tubes containing ethylene-diamine-tetraacetic acid while the subjects were in a supine position. The blood was centrifuged at 4°C to separate plasma, and stored below –20°C until analysis. Plasma BNP concentrations were measured using chemiluminescent enzyme immunoassay kits (Shionogi BNP; Shionogi & Co., Ltd., Osaka, Japan) [34].

### Heart Rate Variability

Holter ambulatory ECG was recorded for every subject to evaluate heart rate variability (HRV). The measurements of heart

rate adopted in the present study were standard deviation of NN intervals (SDNN) and co-variance of NN intervals (CVNN).

Heart periods with arrhythmia were excluded from the HRV analyses.

### Echocardiography

Echocardiograms were recorded for each subject from the parasternal and apical windows. Two-dimensionally guided M-mode echocardiography was performed, and the measurements were expressed as indices [35]. Variables of systolic functions included: left ventricular diastolic dimension (LVDd), left ventricular end-systolic dimension (LVDs), ejection fraction (EF) defined as (LVDd3 – LVDs3)/LVDd3, and fractional shortening (FS) defined as (LVDd – LVDs)/LVDd. FS < 28% and EF < 54% were considered abnormal [36]. The end-diastolic and end-systolic phases were defined as the beginning of the QRS wave of the ECG tracing and the point at which the second heart sound was recorded by the phonocardiogram, respectively. The variable of diastolic function was the ratio between early (E) and late or atrial (A) ventricular filling velocity (the E/A ratio) [37,38] by a pulsed Doppler measurement. The sample volume was placed between the mitral anulus and the leaflet tips where the greatest velocities were found. Cardiac dysfunction was defined by abnormal FS, and abnormalities of the other determinations were used as confirmatory evidence.

### The 6-Minute Walk Test

The 6-min walk test (6MWT) was used to evaluate the functional capacity of the subjects. The field test was performed on a running track to measure the furthest distance a subject can walk. Normal values according to age and sex were defined by Geiger et al. [39].

### Statistical Analyses

Regression analyses were used to study the correlation between cumulative THP dose on one side and cardiac function and biomarkers. The unpaired Student's *t*-test was used for the comparison of mean values. SPSS statistical analysis software (SPSS 12.0 J, SPSS Japan Inc., Tokyo, Japan) was used for all computations.

## RESULTS

Cumulative dose of THP ranged from 120 to 740 mg/m<sup>2</sup> with a median of 180 mg/m<sup>2</sup>. In addition to THP, subjects in ALL941 and ALL2000 received DOX. Thus, total cumulative doses of AC (THP + DOX) ranged from 135 to 812 mg/m<sup>2</sup> with a median of 207 mg/m<sup>2</sup> (Table I). To calculate this, the DOX/THP ratio used was 1:1.08 based on the molecular weight ratio.

The measurements of cardiac functions and the number of abnormal subjects are listed in Table II. ECG at rest was normal in all subjects. However, abnormal ST elevation on ECG was found after laboratory exercise testing in one subject (1.6%). The Holter recording was performed on 59 subjects, and abnormal findings with supra-ventricular premature contraction were detected in 2 (3.3%). These two did not show any other cardiac abnormal measurements. Heart rate variability was normal in all

**TABLE II. Measurements of Cardiac Functions**

Tests	Measurements	Number of subjects	Results mean ± SD (range)	Number of abnormal subjects
ECG	At rest	61	Normal	0
	After exercise	61	ST elevation	1
Holter ECG	Arrhythmia	59	SVPC	2
	CVNN (%)	59	19.8 ± 3.2 (2.7–27.1)	0
Echocardiography	LVDd (mm)	61	43.9 ± 4.0 (36.1–52.0)	0
	LVDs (mm)	61	26.9 ± 3.4 (19.0–34.6)	0
	EF (%)	61	70.4 ± 6.2 (53.0–81.3)	1
	FS (%)	61	38.7 ± 4.6 (29.4–50.0)	0
	E/A ratio	48	2.08 ± 0.47 (1.43–4.0)	0
6MWT	Total (m)	41	563.4 ± 142.5	5
	Males (m)	18	650.4 ± 110.9 (362.0–904.5)	1
	Females (m)	23	495.4 ± 126.7 (252.0–699.6)	4
Laboratory exercise testing	BNP at rest (pg/ml)	60	13.3 ± 14.6 (2.0–70.8)	6
	BNP after exercise (pg/ml)	60	15.1 ± 15.4 (2.0–85.2)	6

6MWT, 6-min walk test; CVNN, co-variance of NN intervals; LVDd, left ventricular end-diastolic dimension; LVDs, left ventricular end-systolic dimension; EF, ejection fraction; FS, fractional shortening; SVPC, supra-ventricular premature contraction.

**TABLE III. Plasma BNP Levels in Patients and Controls**

	BNP (pg/ml)		
	At rest	After exercise	Difference
Patients (n = 60)	13.3 ± 14.7	15.1 ± 15.5	1.8 ± 8.7
Control (n = 10)	10.7 ± 9.3	11.1 ± 10.5	0.4 ± 1.8
<i>P</i>	0.60	0.53	0.63

Values are expressed as mean ± SD.

subjects. Echocardiographic studies showed no cardiac dysfunction, and abnormal measurement was recorded in only one subject with a subnormal EF value of 53%. The 6MWT was performed on 41 subjects, and a significantly short distance as compared to the standard values adjusted to sex and age was recorded in 5 (one male and 4 females). The elevated plasma BNP levels defined as greater than the mean + 2 SD of the 10 healthy controls were >28.3 pg/ml (before exercise) and >31.1 pg/ml (after exercise),

respectively. Based on this criterion, abnormal BNP levels were detected in six subjects whose values were elevated both at rest and after exercise. The mean BNP values before and after exercise in patients and control subjects are shown in Table III, revealing no significant difference between the patients and controls.

Overall, some abnormal cardiac measurements were detected in 14 subjects, and the type of abnormality and cumulative AC dose for each subject are shown in Table IV.

Table V shows the correlation between cumulative THP dose and various cardiac measurements. The cumulative dose showed a significant correlation with plasma BNP levels after exercise (Fig. 1), but not with any other cardiac measurements. Further analysis of the plasma BNP levels after exercise revealed that 21 subjects who received a high cumulative dose ≥ 300 mg/m<sup>2</sup> of THP had significantly higher BNP levels as compared with 39 other subjects who received a low cumulative dose < 300 mg/m<sup>2</sup> (Table VI). This table also shows increments in BNP levels (ΔBNP) after exercise compared to base-line values (at rest) between the two groups. A significant rise in ΔBNP after exercise

**TABLE IV. Cumulative Dose of Anthracyclins and Abnormal Cardiac Measurements**

Case	Cumulative dose of anthracyclins (DOX/THP) (mg/m <sup>2</sup> )	Exercise ECG	Holter ECG	6MWT	Plasma BNP	
					At rest	After exercise
1	25/180	–	+	–	–	–
2	0/180	–	–	+	–	–
3	25/160	–	–	–	+	+
4	75/600	–	–	–	+	+
5	75/730	+	–	–	–	–
6	75/150	–	+	–	–	–
7	75/120	–	–	+	–	–
8	75/740	–	–	–	+	+
9	75/590	–	–	–	+	+
10	15/160	–	–	–	+	+
11	0/135	–	–	–	+	+
12	25/180	–	–	+	–	–
13	25/180	–	–	+	–	–
14	75/740	–	–	+	–	–

+ and – denote positive and negative results for cardiac measurements, respectively. DOX, doxorubicin; THP, pirarubicin.



**TABLE V. Correlation of Cardiac Measurements and Total Dose of THP**

Measurements	Correlation coefficient	P
FS	0.01	0.09
EF	0.90	0.49
E/A ratio	0.08	0.57
CVNN	0.26	0.08
6MWT	0.02	0.88
BNP at rest	0.11	0.42
BNP after exercise	0.27	0.03


THP, pirarubicin; FS, fractional shortening; EF, ejection fraction. CVNN, co-variance of NN intervals; 6MWT, 6-min walk test.

was observed for subjects with  $\geq 300$  mg/m<sup>2</sup> of THP, but not for subjects with  $<300$  mg/m<sup>2</sup> of THP. Although correlations between the measurements of left ventricular function (FS and EF) and cumulative THP dose or BNP levels were studied, no significant results were obtained (Supplemental Appendix).

## DISCUSSION

THP is a derivative of DOX developed in Japan, and its cardiotoxicity may be lower than that of DOX [12–15]. Tsurumi et al. and Niitsu et al. reported that acute cardiotoxicity with THP was less frequent than that with DOX among adult lymphoma patients [17–20]. However, no studies for late cardiotoxicity of THP have been reported. In this study, cardiac function and biomarkers were measured in long-term survivors with ALL who received THP treatment and in whom no apparent cardiac dysfunction was detected. Thus, this is the first report of late cardiotoxicity of THP in cancer survivors.

The incidence of AC-induced cardiac dysfunction in childhood cancer survivors varied considerably across studies. The incidences of 14–24% for cardiac dysfunction assessed by echocardiography had been reported in five studies, in which median doses of cumulative AC ranged from 165 to 450 mg/m<sup>2</sup> [6,7,28,29,31]. Three other studies also reported that cumulative AC dose was significantly associated with reduced FS function, and high cumulative dose  $>300$  mg/m<sup>2</sup> increased the risk of cardiac dysfunction [11,26,27]. When our results are compared with these findings, it appears that incidence of cardiac dysfunction after THP treatment



**Fig. 1.** Correlation between plasma BNP values after exercise and cumulative pirarubicin (THP) dose.

*Pediatr Blood Cancer* DOI 10.1002/pbc

**TABLE VI. Plasma BNP Levels According to Total Dose of THP**

Total dose of THP	$<300$ mg/m <sup>2</sup> (n = 39)	$\geq 300$ mg/m <sup>2</sup> (n = 21)	P value vs. $<300$ mg/m <sup>2</sup>
BNP at rest (pg/ml)	12.5 $\pm$ 13.8	14.8 $\pm$ 15.8	0.56
BNP after exercise (pg/ml)	12.2 $\pm$ 9.9	20.6 $\pm$ 21.2	0.04
$\Delta$ BNP (pg/ml)	-0.3 $\pm$ 7.8	5.4 $\pm$ 8.1	0.01

Values are expressed as mean  $\pm$  SD. THP, pirarubicin.

is relatively low. However, it should be noted that EF and FS may not be sensitive parameters for monitoring cardiac injury, because they often remain normal until critical point in the face of cardiac compensation [30]. Tissue Doppler echocardiography (TDE) has become widely available. Since TDE gives a more precise estimation for diastolic dysfunction than the E/A ratio used in this study, it may be helpful in future studies [40].

Non-invasive techniques for identifying patients who are at high-risk of developing AC-induced cardiomyopathy are critically important. For this purpose, natriuretic peptides including BNP and N-terminal fragment of BNP pro-hormone (NT-pro-BNP), are currently used for detection of cardiac injury in both adults and children [41]. Until now, 4 studies have reported BNP levels in childhood cancer survivors who received AC therapy [28–31]. In 3 of these, elevated BNP levels were detected [28,30,31], although the values did not significantly correlate with cumulative AC doses. Our study showed no significantly different BNP levels in patients from controls, but BNP levels after exercise were significantly correlated to cumulative THP dose. A similar finding was reported by Pinarli et al. [30], in which they found high BNP levels after exercise by treadmill, but no correlation with cumulative AC dose. Since augmented response in plasma BNP levels to exercise has been reported in adult patients with left ventricular dysfunction or exercise-induced ischemia [42,43], the increased BNP levels and  $\Delta$ BNP after exercise in our study may be associated with subclinical myocardial injury. The stability of BNP in blood samples should be considered when interpreting BNP values after exercise. McNairy et al. found that post-exercise BNP returned to baseline levels within 60 min for normal subjects [44]. On the other hand, NT-pro-BNP is characterized by its stability against protease and longer half-life in comparison with BNP. Thus, the measurement of NT-pro-BNP may provide additional evidence in the early detection of anthracycline-induced cardiotoxicity in childhood and adolescence.

Currently, the 6MWT is considered to represent the most suitable method to assess the exercise tolerance. This self-paced test is easy to perform, well tolerated, and highly acceptable to children [39,45]. In our study, all subjects finished the test without difficulty or premature stopping. Consequently, the 6MWT may be used both in assessment and follow up of functional capacity in childhood cancer survivors.

In conclusion, the present study suggested that THP-induced late cardiac dysfunction is rare. However, further investigation is warranted to clarify the pathophysiological significance of elevated BNP levels after the exercise test in asymptomatic patients.

## ACKNOWLEDGMENT

We thank the patients who enrolled in this study and their families, and Paul Lewis for preparation of the manuscript.

## REFERENCES

- Hitchcock-Bryan S, Gelber R, Cassady JR, et al. The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia. *Med Pediatr Oncol* 1986;14: 211–215.
- Smith MA, Ungerleider RS, Horowitz ME, et al. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. *J Natl Cancer Inst* 1991;83:1460–1470.
- Giantris A, Abdurrahman L, Hinkle A, et al. Anthracycline-induced cardiotoxicity in children and young adults. *Crit Rev Oncol Hematol* 1998;27:53–68.
- Scully RE, Lipshultz SE. Anthracycline cardiotoxicity in long-term survivors of childhood cancer. *Cardiovasc Toxicol* 2007;7: 122–128.
- Beneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: A systematic review and meta-analysis. Childhood Acute Lymphoblastic Leukaemia Collaborative Group (CALLCG). *Br J Haematol* 2009;145:376–388.
- Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. *N Engl J Med* 1991;324:808–815.
- Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4–20 years after completing anthracycline therapy. *JAMA* 1991;266: 1672–1677.
- Krischer JP, Epstein S, Cuthbertson DD, et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Group experience. *J Clin Oncol* 1997; 15:1544–1552.
- Kremer LC, van Dalen EC, Offringa M, et al. Anthracycline-induced clinical heart failure in a cohort of 607 children: Long-term follow-up study. *J Clin Oncol* 2001;19:191–196.
- Sorensen K, Levitt GA, Bull C, et al. Late anthracycline cardiotoxicity after childhood cancer: A prospective longitudinal study. *Cancer* 2003;97:1991–1998.
- Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. *J Clin Oncol* 2005; 23:2629–2636.
- Umezawa H, Takahashi Y, Kinoshita M, et al. Tetrahydropyranil derivatives of daunomycin and adriamycin. *J Antibiot* 1979;32: 1082–1084.
- Takagi T, Oguro M. (2-R)-4-o-Tetrahydropyraniladriamycin, a new anthracyclin derivative; its effectiveness in lymphoid malignancies. *Cancer Chemother Pharmacol* 1987;20:151–154.
- Takagi T, Sakai C, Oguro M. Combination chemotherapy with pirarubicin (THP), cyclophosphamide, vincristine, and prednisolone (VEP-THP therapy) in the treatment of non-Hodgkins lymphoma. *Oncology* 1990;47:25–28.
- Miller AA, Salewski E. Prospects for pirarubicin. *Med Pediatr Oncol* 1994;22:261–268.
- Aoki S, Tsukada N, Nomoto N, et al. Effect of pirarubicin for elderly patients with malignant lymphoma. *J Exp Clin Cancer Res* 1998;17:465–470.
- Niitsu N, Umeda M. Biweekly THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for intermediate- and high-grade non-Hodgkins's lymphoma. *Leukemia* 1998;12:1457–1460.
- Niitsu N, Umeda M. Response and adverse drug reactions to combination chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma: Comparison of CHOP, COP-BLAM, COP-BLAM III, and THP-COPBLM. *Eur J Haematol* 1999;63: 337–344.
- Tsurumi H, Yamada T, Sawada M, et al. Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: A randomized phase II study. *J Cancer Res Clin Oncol* 2004;130:107–113.
- Zhai L, Guo C, Cao Y, et al. Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin's lymphoma: Single center, 15-year experience. *Int J Hematol* 2010;91:78–86.
- Kawa K, Ohnuma N, Kaneko M, et al. Long-term survivors of advanced neuroblastoma with MYCN amplification: A report of 19 patients surviving disease-free for more than 66 months. *J Clin Oncol* 1999;17:3216–3220.
- Kaneko M, Tsuchida Y, Mugishima H, et al. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. *J Pediatr Hematol Oncol* 2002;24:613–621.
- Tsurusawa M, Taga T, Horikoshi Y, et al. Favourable outcomes in children with diffuse large B-cell lymphoma treated by a short-term ALL-like regimen: A report on the NHL960 study from the Japanese Childhood Cancer and Leukemia Study Group. *Leuk Lymphoma* 2008;49:734–739.
- Tsurusawa M, Shimomura Y, Asami K, et al. Long-term results of the Japanese Childhood Cancer and Leukemia Study Group studies 811, 841, 874 and 911 on childhood acute lymphoblastic leukemia. *Leukemia* 2010;24:335–344.
- Yamaji K, Okamoto T, Yokota S, et al. Minimal Residual Disease-based Augmented Therapy in Childhood Acute Lymphoblastic Leukemia: A Report from The Japanese Childhood Cancer and Leukemia Study Group Study. *Pediatr Blood Cancer* 2010;55: 1287–1295.
- Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. *N Engl J Med* 1995;332:1738–1743.
- Nysom K, Holm K, Lipsitz SR, et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. *J Clin Oncol* 1998; 16: 545–550.
- Hayakawa H, Komada Y, Hirayama M, et al. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy. *Med Pediatr Oncol* 2001;37:4–9.
- Poutanen T, Tikanoja T, Riikonen P, et al. Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children. *J Clin Oncol* 2003;21:2349–2356.
- Pinarli FG, Oguz A, Tunaoglu FS, et al. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy. *Pediatr Blood Cancer* 2005;44:370–377.
- Aggarwal S, Pettersen MD, Bhambhani K, et al. B-Type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children. *Pediatr Blood Cancer* 2007;49:812–816.
- The criteria committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels, 9th edition. Boston, MA: Little, Brown & Co; 1994.
- Fletcher GF, Balady GJ, Amsterdam EA, et al. Exercise standards for testing and training: A statement for healthcare professionals from the American Heart Association. *Circulation* 2001;104: 1694–1740.
- Shimosaka K, Takahashi A, Saitou H, et al. Evaluation of automated chemiluminescent immunoassay analyzer exclusive kit "MI02 Shionogi BNP". *Igaku to Yakugaku* 2005;53:353–360 (in Japanese).

35. Sahn DJ, DeMaria A, Kisslo J, et al. Recommendations regarding quantification in M-mode echocardiography: Result of a survey of echocardiographic measurements. *Circulation* 1978; 58:1072–1083.
36. Kimball TR, Michelfelder EC. Echocardiography, in Moss & Adams's "Heart Disease in Infants, Children, and Adolescents", 8th edition. Philadelphia: Lippincott Williams & Wilkins; 2008, pp. 95–162.
37. Bu'Lock FA, Mott MG, Oakhill A, et al. Left ventricular diastolic filling patterns associated with progressive anthracycline-induced myocardial damage: A prospective study. *Pediatr Cardiol* 1999;20:252–263.
38. Dorup I, Levitt G, Sullivan I, et al. Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer: The role of diastolic function. *Heart* 2004;90:1214–1216.
39. Geiger R, Strasak A, Treml B, et al. Six-minute walk test in children and adolescents. *J Pediatr* 2007;150:395–399.
40. Civilibal M, Caliskan S, Oflaz H, et al. Left ventricular function by 'conventional' and 'tissue Doppler' echocardiography in paediatric dialysis patients. *Nephrology (Carlton)* 2009;14:636–642.
41. Mavinkurve-Groothuis AM, Kapusta L, Nir A, et al. The role of biomarkers in the early detection of anthracycline-induced cardiotoxicity in children: A review of the literature. *Pediatr Hematol Oncol* 2008;25:655–664.
42. Kato M, Kinugawa T, Ogino K, et al. Augmented response in plasma brain natriuretic peptide to dynamic exercise in patients with left ventricular dysfunction and congestive heart failure. *J Intern Med* 2000;248:309–315.
43. Foote RS, Pearlman JD, Siegel AH, et al. Detection of exercise-induced ischemia by changes in B-type natriuretic peptides. *J Am Coll Cardiol* 2004;44:1980–1987.
44. McNairy M, Gardetto N, Clopton P, et al. Stability of B-type natriuretic peptide levels during exercise in patients with congestive heart failure: Implications for outpatient monitoring with B-type natriuretic peptide. *Am Heart J* 2002;143:406–411.
45. Moalla W, Gauthier R, Maingourd Y, et al. Six-minute walking test to assess exercise tolerance and cardiorespiratory responses during training program in children with congenital heart disease. *Int J Sports Med* 2005;26:756–762.

# Oncogenic LMO3 Collaborates with HEN2 to Enhance Neuroblastoma Cell Growth through Transactivation of *Mash1*

Eriko Isogai<sup>1,2</sup>, Miki Ohira<sup>2</sup>, Toshinori Ozaki<sup>3</sup>, Shigeyuki Oba<sup>4</sup>, Yohko Nakamura<sup>1</sup>, Akira Nakagawara<sup>1\*</sup>

**1** Division of Biochemistry and Innovative Cancer Therapeutics, Chiba Cancer Center Research Institute, Chuoh-ku, Chiba, Japan, **2** Laboratory of Cancer Genomics, Chiba Cancer Center Research Institute, Chuoh-ku, Chiba, Japan, **3** Laboratory of Anti-Tumor Research, Chiba Cancer Center Research Institute, Chuoh-ku, Chiba, Japan, **4** Integrated Systems Biology Laboratory, Department of Systems Science, Graduate School of Informatics, Kyoto University, Gokasho, Uji, Kyoto, Japan

## Abstract

Expression of *Mash1* is dysregulated in human neuroblastoma. We have also reported that LMO3 (LIM-only protein 3) has an oncogenic potential in collaboration with neuronal transcription factor HEN2 in neuroblastoma. However, the precise molecular mechanisms of its transcriptional regulation remain elusive. Here we found that LMO3 forms a complex with HEN2 and acts as an upstream mediator for transcription of *Mash1* in neuroblastoma. The high levels of *LMO3* or *Mash1* mRNA expression were significantly associated with poor prognosis in 100 primary neuroblastomas. The up-regulation of *Mash1* remarkably accelerated the proliferation of SH-SY5Y neuroblastoma cells, while siRNA-mediated knockdown of *LMO3* induced inhibition of growth of SH-SY5Y cells in association with a significant down-regulation of *Mash1*. Additionally, overexpression of both LMO3 and HEN2 induced expression of *Mash1*, suggesting that they might function as a transcriptional activator for *Mash1*. Luciferase reporter assay demonstrated that the co-expression of LMO3 and HEN2 attenuates HES1 (a negative regulator for *Mash1*)-dependent reduction of luciferase activity driven by the *Mash1* promoter. Chromatin immunoprecipitation assay revealed that LMO3 and HEN2 reduce the amount of HES1 recruited onto putative HES1-binding sites and E-box within the *Mash1* promoter. Furthermore, both LMO3 and HEN2 are physically associated with HES1 by immunoprecipitation assay. Thus, our present results suggest that a transcriptional complex of LMO3 and HEN2 may contribute to the genesis and malignant phenotype of neuroblastoma by inhibiting HES1 which suppresses the transactivation of *Mash1*.

**Citation:** Isogai E, Ohira M, Ozaki T, Oba S, Nakamura Y, et al. (2011) Oncogenic LMO3 Collaborates with HEN2 to Enhance Neuroblastoma Cell Growth through Transactivation of *Mash1*. PLoS ONE 6(5): e19297. doi:10.1371/journal.pone.0019297

**Editor:** Laszlo Tora, Institute of Genetics and Molecular and Cellular Biology, France

**Received:** December 21, 2010; **Accepted:** March 31, 2011; **Published:** May 5, 2011

**Copyright:** © 2011 Isogai et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This work was supported in part by a Grant-in-Aid from the Ministry of Health, Labour and Welfare for the Third Term Comprehensive Control Research for Cancer; a Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Culture, Sports, Science and Technology, Japan; and a Grant-in-Aid for Scientific Research from Japan Society for the Promotion of Science. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

\* E-mail: akiranak@chiba-cc.jp

## Introduction

Neuroblastoma is one of the typical childhood cancers and is originated from sympathetic cell lineage of the neural crest [1,2]. Since the tumor never occurs from the other lineages of the neural crest, the oncogenic events to cause neuroblastoma might be strictly regulated in a lineage-specific manner [1,2].

LIM-only protein (LMO) family is composed of four members, LMO1, LMO2, LMO3 and LMO4. Although LMO proteins lack a DNA-binding activity, accumulating evidence suggest that LMO proteins are involved in transcriptional regulation of specific target genes in collaboration with other transcription factors [3]. Genetic analyses demonstrated that LMO1 and LMO2 contribute to the genesis of immature and aggressive T-cell leukemia [4], whereas LMO4 was implicated in development of breast cancer [5,6]. Previously, we reported that *LMO3* is expressed at significantly high levels in human unfavorable neuroblastomas relative to favorable ones, and has an oncogenic potential in neuroblastoma [7]. LMO3 formed a complex with neuronal-specific basic helix-loop-helix (bHLH) transcription

factor HEN2, which was also expressed at higher levels in unfavorable neuroblastoma than favorable one, raising a possibility that LMO3 may form a complex with HEN2 and play an important role in genesis and development of neuroblastoma through transcriptional regulation of as yet unidentified target gene(s).

A proneural bHLH transcription factor termed *Mash1* plays a critical role in development of sympathetic neuron and is highly expressed in neuroblastoma [8,9]. However, its possible contribution to development of neuroblastoma remains elusive. A bHLH protein termed HES1 acts as a negative regulator for *Mash1* [10]. Intriguingly, studies in *Drosophila* demonstrated that expression levels of *achaete-scute*, a *Drosophila* homolog of *Mash1*, are remarkably induced by a transcriptional complex composed of *Drosophila* homolog of LMO (dLMO) and bHLH proteins [11,12].

In this study, we examined whether there could exist functional relationship between LMO3/HEN2 and *Mash1* in neuroblastoma, and found that LMO3/HEN2 attenuates HES1 function and enhances transactivation of *Mash1*, leading to aggressive phenotype of neuroblastoma.